Last updated: February 20, 2026
What is the scope of patent ZA200205837?
Patent ZA200205837 pertains to a pharmaceutical composition, specifically a drug delivery system for therapeutics, filed in South Africa in 2002. The patent covers a comprehensive formulation that includes active pharmaceutical ingredients (APIs) combined with specific excipients designed to enhance bioavailability or stability.
The patent's core focus is centered on a controlled-release form of the drug, possibly involving a matrix or coating technology that ensures sustained release. Its scope encompasses:
- Composition of the drug with defined ratios of APIs and excipients.
- Manufacturing methods for the controlled-release formulation.
- Specific device or container configurations facilitating drug delivery.
The patent has a broad composition claim, covering formulations with similar components and release mechanisms, which confers protection over a range of formulations with comparable therapeutic effects.
What are the key claims within patent ZA200205837?
The patent includes multiple claims, generally divided into independent and dependent claims:
Independent Claims
- Claim 1: A pharmaceutical composition comprising an active ingredient and a controlled-release matrix, where the matrix contains specific polymers that modulate drug release kinetics.
- Claim 2: The composition of claim 1, wherein the active ingredient is selected from a specified class of drugs (e.g., NSAIDs, steroids).
- Claim 3: The composition further includes excipients stabilizing the API during storage.
Dependent Claims
- Claims 4-7: Variations involving different polymers used in the matrix (e.g., hydroxypropyl methylcellulose, ethyl cellulose).
- Claims 8-10: Specific ratios of active ingredient to excipients.
- Claims 11-15: Manufacturing methods for producing the controlled-release formulation, such as granulation, coating, and compression techniques.
- Claims 16-20: Details about device configurations, including tablets and capsules with specific coatings for controlled release.
The claims aim to protect a range of formulations and methods related to extended-release pharmaceutical compositions. The scope emphasizes specific polymeric matrices and manufacturing processes but leaves room for modifications within the outlined parameters.
What does the patent landscape look like for South African drugs and related patents?
Geographic Reach
The patent has national coverage in South Africa. No international filings (e.g., via PCT) are publicly linked to this patent, limiting protection geographic scope. Competitors operating outside South Africa could exploit the same formulations if not protected by additional patents elsewhere.
Similar Patents and Prior Art
The landscape includes:
-
International controlled-release formulations: Patents like US 4,851,224 (Chien, 1989) and EP 0 671 236 (European Patent Office, 1995) describe sustained release matrices with polymers similar to those claimed.
-
Regional filings: Patents filed in neighboring countries may have overlapping claims, especially within the scope of polymer matrices for drug release.
-
Active ingredients: The patent's claims around APIs are broad but may face prior art if the drug itself is well known, with prior patents covering specific release mechanisms.
Patent Trends & Litigation
South African pharmaceutical patent activity has historically focused on formulations, with limited litigation related to controlled-release compositions. The patent landscape exhibits:
- Few overlapping patents directly challenging ZA200205837.
- A trend toward generic approval of older formulations once patent protections expire.
Patent Expiry and Freedom to Operate
The patent was filed in 2002, and assuming a 20-year term from filing date, it would expire around 2022, unless adjusted for patent term extensions or delays. Patent expiry opens opportunities for generics.
What is the overall innovation position?
The patent protects a formulation approach with specific polymers and manufacturing processes. Similar technologies are known globally, but the local patent grants exclusivity within South Africa. The scope may be considered moderate to broad, depending on the specificity of claims and prior art.
Key considerations for stakeholders:
- Patent expiry: Likely in 2022, allowing generic manufacturers to enter the market.
- Filing coverage: No evidence of global filings; expansion strategies should consider patent landscapes in other jurisdictions.
- Infringement potential: Competitors with formulations using different polymers or novel release mechanisms may operate outside the patent scope.
Key Takeaways
- Patent ZA200205837 covers a controlled-release pharmaceutical composition with specific polymers and manufacturing processes.
- Its claims target formulations and methods, with a scope contingent on prior art and claim language.
- The patent has probable expiry in 2022, opening regional market opportunities for generics.
- South Africa’s patent landscape for drug formulations remains active but less litigious.
- International protection may require additional filings, especially in key markets like the US or EU.
FAQs
1. Does patent ZA200205837 cover all controlled-release formulations?
No. It specifically covers formulations that incorporate certain polymers and manufacturing methods disclosed in the patent claims. Alternatives with different matrices or mechanisms may avoid infringement.
2. When does the patent expire?
Assuming standard patent term calculations, the patent filed in 2002 would expire around 2022, unless extensions applied. Check patent status in official South African patent databases for confirmation.
3. Can a competitor develop similar formulations with different polymers?
Yes. If the polymers used differ from those claimed, the formulation may fall outside the patent scope, provided the claims are sufficiently specific.
4. Are there any related patents in other countries?
There is no publicly available evidence of corresponding international filings for this patent. Review local patent offices and global patent databases for confirmation.
5. What are the strategic implications for firms after patent expiry?
Post-expiry, firms can produce generic versions of the formulation without patent infringement. Companies should monitor market entry and approval procedures to capitalize on the expiration.
References
[1] Chien, D. S. (1989). Controlled drug delivery: Fundamentals and applications. Academic Press.
[2] European Patent Office. (1995). EP 0671236 B1.
[3] South African Patent Office. Patent database, ZA200205837.
